|Mr. James R. Sapirstein R.Ph., M.B.A.||CEO, Pres & Non-Independent Director||443.61k||N/A||1961|
|Dr. James E. Pennington||Chief Medical Officer||330k||N/A||1943|
|Mr. Martin Krusin M.B.A.||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Mr. Daniel H. Schneiderman||Chief Financial Officer||N/A||N/A||1978|
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company's therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.
AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.